(in thousands)
Gross profit on a GAAP basis 58% 59%
Share-based compensation expense:
- Cost of product sales 1% 1%
Gross profit on a non-GAAP basis 59% 60%
Diluted net income/(loss) per share
reconciliation For the Fiscal Year Ended 2008
From To
(in thousands, except per share data)
Diluted net income (loss) per share on a
GAAP basis $0.20 $0.26
Share-based compensation expense 0.20 0.20
Amortization of purchased intangibles 0.21 0.21
Income tax effect of non-GAAP
adjustments (0.14) (0.15)
Diluted net income per share on a
non-GAAP basis $0.47 $0.52
Shares used in calculation of diluted
net income (loss) per share -- GAAP 62,801 62,801
Shares used in calculation of
diluted net income per share -- non-
GAAP (a) 62,801 62,801
(a) Shares used in the per share calculation for reconciling items
between GAAP and non-GAAP financial measures.
Thoratec is a world leader in therapies to address advanced stage heart
failure. The company's product lines include the Thoratec(R) VAD and
HeartMate LVAS with nearly 12,000 devices implanted in patients suffering
from heart failure. Additionally, its International Technidyne Corporation
(ITC) Division supplies point-of-care blood testing and skin incision
products. Thoratec is headquartered in Pleasanton, California. For more
information, visit the company's web sites at
| SOURCE Thoratec Corporation Copyright©2008 PR Newswire. All rights reserved |